<DOC>
	<DOC>NCT01748695</DOC>
	<brief_summary>The purpose of this study is to investigate whether V158866 is safe and effective for the treatment of neuropathic pain due to spinal cord injury.</brief_summary>
	<brief_title>A Safety, Tolerability and Efficacy Study of V158866 in Central Neuropathic Pain Following Spinal Cord Injury</brief_title>
	<detailed_description />
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<criteria>aged 18 65 years documented spinal cord injury at or below T5 moderate pain at or below the level of the spinal cord injury for at least 3 months compliant with daily diary stable pain scores on the NRS mean pain intensity of at least 4 and not more than 9 on the NRS (or if the mean NRS score is &gt;9, the mean Gracely score must be â‰¤19) women of childbearing potential men who intend to father a child a history of multiple drug allergies, hypersensitivity to any cannabinoid an increased risk of seizure evidence of depression and/or a score of &gt;19 on the BDIII suicidal ideation or suicidal behavior in the past 10 years a history of substance abuse or dependence within the past year, excluding nicotine and caffeine a positive urine test for cannabis at screening taking excluded medications that cannot be stopped a positive pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Neuropathic pain</keyword>
	<keyword>Spinal cord injury</keyword>
</DOC>